MeSH

One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.

Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS.

Year introduced: 2015

A phosphoprotein that was initially identified as a major target of DOPAMINE activated ADENYLYL CYCLASE in the CORPUS STRIATUM. It regulates the activities of PROTEIN PHOSPHATASE-1 and PROTEIN KINASE A, and it is a key mediator of the biochemical, electrophysiological, transcriptional, and behavioral effects of DOPAMINE.

Year introduced: 2006(1984)

A subtype of dopamine D1 receptors that has higher affinity for DOPAMINE and differentially couples to GTP-BINDING PROTEINS.

Year introduced: 2006(1991)

A subtype of dopamine D2 receptors that has high affinity for the antipsychotic CLOZAPINE.

Year introduced: 2006(1991)

A subtype of dopamine D2 receptors that are highly expressed in the LIMBIC SYSTEM of the brain.

Year introduced: 2006(1987)

Sodium chloride-dependent neurotransmitter symporters located primarily on the PLASMA MEMBRANE of dopaminergic neurons. They remove DOPAMINE from the EXTRACELLULAR SPACE by high affinity reuptake into PRESYNAPTIC TERMINALS and are the target of DOPAMINE UPTAKE INHIBITORS.

Year introduced: 2006(1987)

Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.

Year introduced: 1995

Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.

Year introduced: 1995

Drugs that bind to and activate dopamine receptors.

Year introduced: 1995

A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.

Year introduced: 1993

A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES.

Year introduced: 1993

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Year introduced: 1995

Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells.

Year introduced: 1977

Year introduced: 1973(1971)

Functional brain imaging techniques that utilize various RADIONUCLIDE TRACERS that bind to different targets in the SYNAPSES of DOPAMINERGIC NEURONS.

Year introduced: 2023

A congenital syndrome caused by mutations in the dopamine beta-hydroxylase (DBH) gene. It is characterized by ORTHOSTATIC HYPOTENSION; frequent SYNCOPE especially following exercies, BLEPHAROPTOSIS; and delayed eye opening in affected neonates. Norepinephrine is greatly reduced in body fluids while dopamine is greatly increased. OMIM: 223360

Date introduced: August 25, 2010

Neurons whose primary neurotransmitter is DOPAMINE.

Year introduced: 2012

Date introduced: January 22, 2003

D2L acts primarily at postsynaptic site; D2S serves presynaptic autoreceptor functions; the D1-like receptors (D1 and D5) stimulate adenylyl cyclase e, whereas the D2-like receptors (D2,D3 and D4) inhibit adenylyl cyclase

Date introduced: August 21, 1998